Skip to main content
. Author manuscript; available in PMC: 2018 Jan 22.
Published in final edited form as: Bone Marrow Transplant. 2009 Jul 27;45(3):498–504. doi: 10.1038/bmt.2009.176

Figure 1.

Figure 1

(Left panel) Survival from primary treatment for all patients who received or did not receive HDT within the first year. (Right panel) Survival from primary treatment for all patients with myeloma in CR, PR or NR as best outcome.